Biopharmaceutical company put $450 million in Review
Steve’s breakdown: Talk about taking your time. Amgen has officially put its $450 million global media account into review after sending out an RFI last December. These guys are moving so slow you might be able to catch up with 10 month long review.
Try Suzanne Blaug at firstname.lastname@example.org. She’s the Senior Vice President, Global Marketing and Commercial Development but keep in mind, Ark Advisors is the search consultant behind this slow boat to China so you might want to start there. Your call . . .
THOUSAND OAKS, CA: “A spoonful of sugar helps the medicine go down…”
Biopharmaceutical company Amgen has officially put its $450 million global media account into review after sending out a request for information last December, according to people with knowledge of the matter.
Representatives from Amgen declined to comment on the review, which is being led by Ark Advisors, Ad Age has learned. WPP’s MEC Global has worked with Amgen since 2003. Amgen reviews the media business every three years as part of its procurement process.